Posts Tagged ‘Shine on Scotland’

Study CONFIRMS raising vitamin D levels could reduce MS relapses by 50%

Thursday, August 12th, 2010 | Tags: , , , , , , , , , , , , , , , , , , , , , , ,
Posted in External News Articles, Uncategorized

Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis.

Abstract

OBJECTIVE: A protective association between higher vitamin D levels and the onset of multiple sclerosis (MS) has been demonstrated; however, its role in modulating MS clinical course has been little studied. We investigated whether higher levels of serum 25-hydroxyvitamin D (25-OH-D) were associated with a lower risk of relapses in people with MS.

METHODS: We conducted a prospective cohort study of 145 participants with relapsing-remitting MS from 2002 to 2005. Serum 25-OH-D levels were measured biannually, and the hazard of relapse was assessed using survival analysis.

RESULTS: There was an inverse linear relationship between 25-OH-D levels and the hazard of relapse over the subsequent 6 months, with hazard ratio (HR) 0.91 (95% confidence interval [CI]: 0.85-0.97) per 10nmol/l increase in 25-OH-D level (p = 0.006). When variation due to timing of blood collection was removed by estimating 25-OH-D at the start of each season, this association persisted, with HR 0.90 (95% CI, 0.83-0.98) per 10nmol/l increase (p = 0.016). Taking into account the biological half-life of 25-OH-D, we estimated 25-OH-D at monthly intervals, resulting in a slightly enhanced association, with HR 0.88 (95% CI, 0.82-0.95) per 10nmol/l increase (p = 0.001). Adjusting for potential confounders did not alter these findings.

INTERPRETATION: In this prospective population-based cohort study, in a cohort largely on immunomodulatory therapy, higher 25-OH-D levels were associated with a reduced hazard of relapse. This occurred in a dose-dependent linear fashion, with each 10nmol/l increase in 25-OH-D resulting in up to a 12% reduction in risk of relapse. Clinically, raising 25-OH-D levels by 50nmol/l could halve the hazard of a relapse. ANN NEUROL 2010;68:193-203.

Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I.

Menzies Research Institute

Sources: Ann Neurol. 2010 Aug;68(2):193-203. & Pubmed PMID: 20695012 (11/08/10)

msrc.co.uk

Kellogg’s fortify Cereal with Vitamin D

Saturday, August 7th, 2010 | Tags: , , , , , , , ,
Posted in External News Articles, Uncategorized

Company responds to campaigning by health groups with announcement of 15% cut in sugar content in Coco Pops

cocopops2Kellogg’s has pledged to reduce high levels of sugar in its best-selling children’s cereal following a sustained campaign by health groups.

The company announced nutritional improvements to its existing Coco Pops chocolate cereal range, involving a reduction in sugar, the addition of vitamin D and the launch of a new Coco Pops Choc ‘N’ Roll cereal which will pass the Food Standards Agency’s tougher nutrient profile.

The firm said that by this time next year it would remove 15% of sugar in all its Coco Pops cereals, effectively reducing sugar content to one and a half teaspoons a serving and eliminating almost 750 tonnes of sugar from the nation’s diet annually. The sugar will be replaced with starch from grains and glucose syrup, and no artificial sweeteners will be used. Calories will be maintained at approximately 116 a serving.

The new cereal goes on sale in supermarkets tomorrow, backed by a £3m advertising and marketing campaign aimed specifically at mothers, who are predominantly in charge of the family shop.

Kellogg’s ran into controversy earlier this year after a poster advert depicting its famous cartoon monkey, Coco, dressed in school uniform under the slogan: “Ever thought of Coco Pops after school?” The company admitted it had made a mistake by showing the advert on bus shelters and other locations near schools, which meant it was seen by plenty of children. Marketing manager Peter Harrison said those locations were inappropriate.

Greg Peterson, Kellogg’s UK managing director, said: “We’ve listened to what mums have been saying and we’re responding. They want a balance: lower sugar cereals which children will still eat. We’ve invested millions of pounds … to make this happen.”

The company says it also aims to further reduce the sugar content in its Coco Pops products, provided they pass consumer taste tests.

Peterson added: “This is a process, so while we’ve announced we are taking 15% of sugar out by the middle of next year … we will go further if we can take peoples’ palates with us.”

Britons eat 29m boxes of Coco Pops a year, and 40% of UK households with children have the cereal in their kitchen cupboard.

Health and consumer groups welcomed the move, but said it was long overdue and demanded that changes be made to Kellogg’s entire product range. Jackie Schneider, of the Children’s Food Campaign, said: “We are staggered that Coco Pops currently contains 37% sugar per 100g. So this reformulation is long overdue, and it seems odd to us that the changes are being announced now, when the products won’t appear on the shelves until mid-2011 at the earliest.

“Our understanding is that the new Kellogg’s cereal would get a red traffic light, so should not be seen as an everyday food. The good news is that the nutrient profiling model which determines if food can be advertised to children certainly seems to be driving food manufacturers to reduce high levels of fat, salt and sugar. It is good to see Kellogg’s are moving in the right direction, but there is a world of breakfast foods out there that parents might prefer to these sugary cereals”

Katharine Jenner, campaign manager with the health organisation Consensus Action on Salt and Health and a nutritionist at the Wolfson Institute of Preventive Medicine, said: “Keeping children’s salt consumption low is vital. Children who eat higher salt diets are more at risk of higher blood pressure when they are adults, putting them at risk of strokes, heart attacks and heart failure. We are pleased to see Kellogg’s are responding to consumer demand and have not put so much salt into their new Coco Pops Choc ‘N’ Roll product. But all their breakfast cereals, not just this one, should be lower in salt.”

http://www.guardian.co.uk/business/2010/aug/04/kelloggs-cuts-sugar-coco-pops

FSA must put its cards on table now

Monday, August 2nd, 2010 | Tags: , , , , , , , , , ,
Posted in Uncategorized

ryanmclaughlinOver the last few months, I’ve been asking the Scottish Government to obtain confirmation from the Food Standards Agency (FSA) to clarify the safe vitamin D levels for the general UK population from the latest FSA’s  research in Scotland.

To date the FSA is the only UK organisation to carry out vital research on safe vitamin D levels for the general UK population.

Despite the FSA’s own experts publicly saying 1000iu to be deemed to be completely safe for the general population with no risk, the FSA has stalled on publishing its results from its own research carried out in Aberdeen. To make matters worse, on a BBC program on Sunday 1st August 2010, the FSA said that it may take another  4 years to decide to make a decision.

I am 15 years of age, and if I can reach a reasonable conclusion that 1000iu of vitamin d is safe after reading all the evidence available to me, it would take less than 24 hours for the FSA experts to reach a similar conclusion. So I have to ask what is going on?

It is a completely ridiculous situation. The top neurological scientists and MS experts say vitamin D could prevent MS – yet a Food Standards body who have the evidence to hand, and delaying a solution to possibly prevent MS for people all around the world.

I plead with the FSA to publish its research results immediately. We need to open the publics eyes to the amount of vitamin D they require. The FSA’s stalling is only going to put more kids at risk from diseases such as MS. While the FSA experts continue to delay and debate, we kids live each and every day with the results from the lack of action on vitamin D deficency taken by the UK Government and organisations like the FSA.

No more delaying – its time for action.

Ryan Mclaughlin

Shine on Scotland Campaign

Confirmation of association between Multiple Sclerosis, CYP27B1 & Vitamin D

Sunday, July 25th, 2010 | Tags: , , , , , , , , , , , , , , , , , , , , , ,
Posted in External News Articles, Uncategorized

Confirmation of association between multiple sclerosis, CYP27B1 and vitamin D

Multiple sclerosis, MS (OMIM No. 126200), is a complex inflammatory disease that is characterized by lesions in the central nervous system.

Both genes and other environmental factors influence disease susceptibility. One of the environmental factors that has been implicated in MS and autoimmune disease, such as type 1 diabetes, is vitamin D deficiency, in which patients have lower levels of 25-hydroxyvitamin D3 (25-OHD3) in blood than do controls.

Previtamin D3 is produced in the skin, and turned into 25-OHD3 in the liver. In the kidney, skin and immune cells, 25-OHD3 is turned into bioactive 1,25(OH)2D3 by the enzyme coded by CYP27B1 (cytochrome P450 family 27 subfamily B peptide 1) on chromosome 12q13.1–3. 1,25(OH)2D3 binds to the vitamin D receptor, expressed in T cells and antigen-presenting cells.

1,25(OH)2D3 has a suppressive role in the adaptive immune system, decreasing T-cell and dendritic cell maturation, proliferation and differentiation, shifting the balance between T-helper 1 (Th1) and Th2 cells in favor of Th2 cells and increasing the suppressive function of regulatory T cells. Rs703842 in the 12q13–14 region was associated with MS in a recent study by the Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene).

We show associations with three SNPs in this region in our Swedish materials (2158 cases, 1759 controls) rs4646536, rs10877012 and rs10877015 (P=0.01, 0.01 and 3.5 × 10−3, respectively). We imputed rs703842 SNP and performed a joint analysis with the ANZgene results, reaching a significant association for rs703842 (P=5.1 × 10−11; odds ratio 0.83; 95% confidence interval 0.79–0.88).

Owing to its close association with 25-OHD3, our results lend further support to the role of vitamin D in MS pathology.

  1. 1Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
  2. 2Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
  3. 3Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

Correspondence: E Sundqvist, Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institutet, Stockholm 17176, Sweden. Tel: +46 85 177 6258; Fax: +46 85 177 6248; E-mail: Emilie.Sundqvist@ki.se

Received 4 December 2009; Revised 19 March 2010; Accepted 4 June 2010; Published online 21 July 2010.

http://www.nature.com/ejhg/journal/vaop/ncurrent/abs/ejhg2010113a.html

Multiple sclerosis and vitamin D: a review and recommendations.

Sunday, July 25th, 2010 | Tags: , , , , , , , ,
Posted in Uncategorized

Multiple sclerosis and vitamin D: a review and recommendations.

Solomon AJWhitham RH.

Department of Neurology, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, CR 120, Portland, OR 97239, USA. solomoan@ohsu.edu

A relationship between vitamin D and several diseases, including multiple sclerosis (MS), has recently received interest in the scientific community. Vitamin D appears to have important actions beyond endocrine function, particularly for the immune system. Risk of development of MS, as well as disease severity, has been associated with vitamin D in a variety of studies. There remains a need for prospective studies to further establish this relationship. Given the current evidence of the potential benefits of vitamin D, it appears to be reasonable and safe to consider vitamin D supplementation at dosing adequate to achieve normal levels in patients with MS and clinically isolated syndrome.

source : http://www.ncbi.nlm.nih.gov/pubmed/20556546

Lighting the way to better health: vitamin D

Thursday, July 22nd, 2010 | Tags: , , , , , , , ,
Posted in Uncategorized

Lighting the way to better health: vitamin D

17th July 2010

The Lancet

The public health message is compellingly simple: avoid the sun to prevent melanoma and other forms of skin cancer. Unfortunately, exposure to sunlight is the mainstay of vitamin D synthesis, and vitamin D deficiency causes rickets and osteomalacia, contributes to osteoporosis, and has been associated with many other disorders, including diabetes, cancer, and cardiovascular disease.

Ultraviolet B radiation produces 90% of vitamin D in human beings; only a very small proportion can be obtained through diet. However, at high latitudes, levels of sunlight in winter are often so low that vitamin D insufficiency is common. Avoidance of the sun’s rays by covering up or use of sunscreen can compound this problem, and is thought to have contributed to a recent increase in metabolic bone disease. Cancer Research UK recognises the need to balance skin cancer prevention with generation of adequate vitamin D, but specified that “the skin efficiently produces vitamin D at levels of sun exposure below those that cause sunburn…when it comes to sun exposure, little and often is best”. Australia’s SunSmart guidelines underwent a revision to reflect this balance in 2006—07.

A major concern is that people might seek prolonged sun exposure without protection to boost vitamin D synthesis. Indeed, the American Academy of Dermatology argues that the risks of sun exposure outweigh the benefits, advocating instead for dietary supplementation as a safe source of vitamin D. A report published in the British Journal of Nutrition emphasises that in the UK, a unified approach to vitamin D supplementation is needed to address deficiency in pregnant women and avoid life-threatening complications for their babies.

Despite the simmering debate about sun exposure surrounding vitamin D, the SUNLIGHT consortium’s genome-wide association study, published in The Lancet today, should add to our understanding of the genetic basis of interindividual variability in the synthesis of vitamin D. These findings could eventually help to identify who is most at risk of vitamin D insufficiency and related diseases. Until such potential applications come to the fore, the message about sun exposure has to be sensibly moderate. Enjoy the summer sun, with caution.

Source : The lancet

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61094-X/fulltext?elsca1=TL-160710&elsca2=email&elsca3=segment

Scottish Vitamin D Summit Captures International Attention

Wednesday, July 21st, 2010 | Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,
Posted in Uncategorized

Scottish Vitamin D Summit Captures International Attention

For immediate release : July 21st 2010

Shine on Scotland campaigners and the MS Society Scotland held productive talks with the Scottish Government yesterday as planning continues for the Scottish Summit on Vitamin D and MS which will take place in Glasgow in September.

Cabinet Secretary for Health and Wellbeing Nicola Sturgeon will open the event at which international researchers and scientists will be present to discuss the latest research on vitamin D and the implications for public health policy in Scotland.

In recent weeks more researchers from as far afield as Australia have confirmed their attendance at the summit.  International media organisations have also expressed an interest in the event which looks set to be high profile.

Looking ahead to September, Ryan McLaughlin said:

“It’s incredibly exciting that it’s now so close.  A lot of work has gone into the campaign and hopefully this summit will make a real difference.  The Scottish Government and Parliament have been very supportive of the campaign and it’s great to have reached this stage”.

Craig Wilkie, Head of Policy and Communications at MS Society Scotland also attended the meeting at St Andrews House:

“The Summit is a great opportunity to bring internationally renowned researchers to Scotland to discuss a hugely important public health issue.  The focus will be a practical one in terms of public health policy and we have the chance to learn lessons from other countries and make a significant contribution to the health of the nation”.

Vitamin D and Parkinson’s

Sunday, July 18th, 2010 | Tags: , , , ,
Posted in Uncategorized

“Low vitamin D levels may increase a person’s risk of developing Parkinson’s disease,” BBC News has reported. Its website said that people with the lowest levels of vitamin D had a three-fold higher risk of developing Parkinson’s disease.

The news is based on research that followed over 3,000 Finnish people aged 50 to 79 years over a period of 29 years. Scientists took a measurement of the participants’ blood vitamin D levels and looked at how the subsequent risk of developing Parkinson’s disease over the period related to their blood vitamin D levels.

This high-quality, preliminary study showed an increased risk of developing Parkinson’s disease in those patients with the lowest vitamin D levels compared to the highest. However, Finland is a northern latitude country and so all the participants had relatively low levels of vitamin D, which the body produces using sunlight. Further research is needed to follow up whether this association is found in larger cohorts of people from different latitudes, who may have higher vitamin D levels than in this study.

Where did the story come from?

The study was carried out by researchers from the national Institute for Health and Welfare in Finland and was funded by the US National Institutes of Health. The study was published in the peer-reviewed medical journal Archives of Neurology.

This study was covered accurately by BBC News, which pointed out that it is still uncertain if there is a level of vitamin D that is optimal for brain health or a point where vitamin D becomes toxic for humans.

What kind of research was this?

This was a cohort study that looked at whether vitamin D levels in the blood earlier in life are associated with developing Parkinson’s disease later in life.

The researchers suggest that patients with Parkinson’s disease have been found to have lower vitamin D in cross-sectional studies. Problematically, cross-sectional studies, which only look at participants at one point in time, can only tell us about the vitamin D levels found in patients had already developed the disease.

To explore the possible relationship, the researchers wanted to see whether the vitamin D levels predicted Parkinson’s disease several decades later. This research looked at incidence in a population who had been followed for 29 years on average, and who were from northern latitudes (Finland) where exposure to the sun is limited and therefore the vitamin D they derived from the sun was usually low.

What did the research involve?

The researchers used data from the Mini-Finland Health Survey, which was carried out from 1978 to 1980 across 40 areas of Finland. They used data from 3,173 individuals who were free from Parkinson’s disease and psychotic disorders and who were aged between 50 and 79 years at the time of the survey.

The questionnaire contained data on socioeconomic background, medical history and lifestyle as well as baseline examination measurements of height, weight, blood pressure, cholesterol and vitamin D levels in the blood.

Cases of Parkinson’s disease were diagnosed and verified by two separate clinicians; a standard practice in the Finnish health system. Finnish patients with Parkinson’s disease can receive free medication after applying with a certificate issued by their treating neurologist. These certificates contain the symptom history and clinical findings in the patients. A neurologist from a social insurance institution then has to agree with the diagnosis described on the certificate for medication costs to be reimbursed.

Patients were followed up for an average of 29 years from their baseline examination until their diagnosis of Parkinson’s disease or death from other causes. During this period 50 members of the cohort developed Parkinson’s disease.

The researchers used an established statistical technique called the ‘Cox proportional hazards model’ to estimate the strength of association (relative risk) between vitamin D levels and the risk of developing Parkinson’s disease.

What were the basic results?

The researchers found that vitamin D concentration was lower among people with Parkinson’s disease but it was also associated with age, sex, marital status, leisure time, physical activity, smoking, alcohol consumption, BMI, diabetes, high blood pressure, blood cholesterol levels and the season in which the measurement was taken.

After adjusting for these confounding factors the researchers found that individuals with higher vitamin D levels had a lower risk of Parkinson’s disease compared to individuals with low vitamin D. The relative risk of developing Parkinson’s disease was 67% lower for the quarter of patients with the highest vitamin D levels, compared to the quarter of patients with the lowest vitamin D.

The researchers suggest that an optimal blood vitamin D concentration is 75-80 nmol/l. People in:

  • the lowest quartile had vitamin D concentrations of 8 to 28 nmol/l (men), 7 to 25 nmol/l (women).
  • the highest quartile had vitamin D concentrations in the range 57 to 159 nmol/l (men), 50 to 151 nmol/l (women).

How did the researchers interpret the results?

The researchers say that a low serum vitamin D level predicts an elevated risk of Parkinson’s disease incidence. They say that although the study population as a whole had low vitamin D levels, a dose-response relationship was found; in other words, the lower the vitamin D level the higher the chance of Parkinson’s disease.

The study did not look at mechanisms underlying the association but the researchers suggest that vitamin D could act as an antioxidant, regulate neuron activity or act through detoxification mechanisms. They also say that an enzyme that makes the active form of vitamin D is found in high concentrations in the substantia nigra, the region of the brain that is affected most by Parkinson’s disease.

An editorial accompanying this research article says that some epidemiological studies have shown a latitudinal north-south gradient for Parkinson’s disease, similar to that seen for multiple sclerosis. However, it cautions that the evidence does not seen to be as strong for Parkinson’s as it is for multiple sclerosis (MS) because other studies have not confirmed the potential link.

The authors say the research study “provides the first promising human data to suggest that inadequate vitamin D status is associated with the risk of developing Parkinson’s disease”. They add that further work is needed in both basic and clinical arenas to understand the exact role, mechanisms, and optimum concentration of vitamin D in Parkinson’s disease.

Conclusion

This was a well-conducted study that looked prospectively at the role of vitamin D in the risk of developing Parkinson’s disease, although there are some limitations to the study that the researchers highlight:

  • There were a small number of cases of Parkinson’s disease within this cohort. The researchers suggest this may have affected the accuracy of their estimates of risk.
  • The study only took a single measurement of vitamin D, which may not reflect typical variations in concentrations across the seasons and across the lifetime of each individual.
  • The blood samples had been stored for a relatively long time so the possibility that the vitamin D levels changed with storage cannot be excluded.
  • The study did not address whether there is a critical time in life that suboptimal vitamin D levels affect the risk of Parkinson’s disease.
  • The study did not include information on dietary intake of vitamin D from vitamin D rich foods such as oily fish. Such foods may contain other nutrients that may be beneficial against Parkinson’s disease.
  • The risk factors for Parkinson’s disease are not well known and therefore not all possible influencing factors may have been taken into account in the analysis.

This relatively small, preliminary study was of good quality but the researchers say that larger follow-up cohort studies are needed. Clinical trials focusing on the effect of vitamin D supplements on the incidence of Parkinson’s disease also merit follow up, they say.

It is worth noting that as this study was conducted in people who all had low levels of vitamin D. It is not known, from this study, if there is a level of vitamin D above which there is no further reduction in the risk of Parkinson’s disease. This is important as excessive amounts of vitamin D taken as supplementation in people with normal levels can cause toxicity.

source: nhs choices

More than half the world’s population gets insufficient vitamin D, says UCR biochemist

Sunday, July 18th, 2010 | Tags: , , , , , , , , , , ,
Posted in Uncategorized

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California – Riverside

RIVERSIDE, Calif. – Vitamin D surfaces as a news topic every few months. How much daily vitamin D should a person get? Is it possible to have too much of it? Is exposure to the sun, which is the body’s natural way of producing vitamin D, the best option? Or do supplements suffice?

In the July 2010 issue of Endocrine Today, a monthly newspaper published by SLACK, Inc., to disseminate information about diabetes and endocrine disorders, Anthony Norman, a distinguished professor emeritus of biochemistry and biomedical sciences and an international expert on vitamin D, notes that half the people in North America and Western Europe get insufficient amounts of vitamin D.

Anthony Norman is a distinguished professor of biochemistry and biomedical sciences (emeritus) at UC Riverside, and an international expert on vitamin D.

Anthony Norman is a distinguished professor of biochemistry and biomedical sciences (emeritus) at UC Riverside, and an international expert on vitamin D.

“Elsewhere, it is worse,” he says, “given that two-thirds of the people are vitamin D-insufficient or deficient. It is clear that merely eating vitamin D-rich foods is not adequate to solve the problem for most adults.”

Currently, the recommended daily intake of vitamin D is 200 international units (IU) for people up to 50 years old; 400 IU for people 51 to 70 years old; and 600 IU for people over 70 years old.

“There is a wide consensus among scientists that the relative daily intake of vitamin D should be increased to 2,000 to 4,000 IU for most adults,” Norman says. “A 2000 IU daily intake can be achieved by a combination of sunshine, food, supplements, and possibly even limited tanning exposure.”

While there is now abundant data on vitamin D and its benefits, Norman believes there is room for more study.

“The benefits of more research on the topic justifies why this field of research deserves additional governmental funding,” he says. “Already, several studies have reported substantial reductions in incidence of breast cancer, colon cancer and type 1 diabetes in association with adequate intake of vitamin D, the positive effect generally occurring within five years of initiation of adequate vitamin D intake.”

Because vitamin D is found in very few foods naturally (e.g. fish, eggs and cod liver oil) other foods such as milk, orange juice, some yogurts and some breakfast foods are fortified with it. The fortification levels aim at about 400 IU per day.

Norman, who holds the title of Presidential Chair in Biochemistry-Emeritus, has been researching vitamin D for nearly 50 years. In 1967, his laboratory discovered that the vitamin is converted into a steroid hormone by the body. Two years later, his laboratory discovered the vitamin D receptor (or VDR), an essential receptor for the steroid hormone form of vitamin D that is present in more than 37 target organs of the body that respond biologically to the vitamin.

“There is now irrevocable evidence that receptors in the immune, pancreas, heart-cardiovascular, muscle and brain systems in the body generate biological responses to the steroid hormone form of vitamin D,” he says.


Hypovitaminosis D – one of the MS risk factors?

Thursday, July 15th, 2010 | Tags: , , , ,
Posted in Uncategorized

The role of hypovitaminosis D as a possible risk factor for multiple sclerosis is reviewed.

First, it is emphasized that hypovitaminosis D could be only one of the risk factors for multiple sclerosis and that numerous other environmental and genetic risk factors appear to interact and combine to trigger the disease.

Secondly, the classical physiological notions about vitamin D have recently been challenged and the main new findings are summarized.
This vitamin could have an important immunological role involving a number of organs and pathologies, including autoimmune diseases and multiple sclerosis. Furthermore, human requirements for this vitamin are much higher than previously thought, and in medium- or high-latitude countries, they might not be met in the majority of the general population due to a lack of sunshine and an increasingly urbanized lifestyle. Thereafter, the different types of studies that have helped to implicate hypovitaminosis D as a risk factor for multiple sclerosis are reviewed.

In experimental autoimmune encephalomyelitis, vitamin D has been shown to play a significant immunological role.

Diverse epidemiological studies suggest that a direct chain of causality exists in the general population between latitude, exposure to the sun, vitamin D status and the risk of multiple sclerosis. New epidemiological analyses from France support the existence of this chain of links.

Recently reported immunological findings in patients with multiple sclerosis have consistently shown that vitamin D significantly influences regulatory T lymphocyte cells, whose role is well known in the pathogenesis of the disease.

Lastly, in a number of studies on serum levels of vitamin D in multiple sclerosis, an insufficiency was observed in the great majority of patients, including at the earliest stages of the disease.
The questionable specificity and significance of such results is detailed here.

Based on a final global analysis of the cumulative significance of these different types of findings, it would appear likely that hypovitaminosis D is one of the risk factors for multiple sclerosis.

Charles Pierrot-Deseilligny1 and Jean-Claude Souberbielle2

1 Service de Neurologie 1, Hoˆ pital de la Salpeˆ trie` re, Assistance Publique Hoˆ pitaux de Paris, Universite´ Pierre et Marie Curie (Paris VI), Paris, France
2 Service d’explorations fonctionnelles, Hoˆ pital Necker-Enfants-Malades, Assistance Publique Hoˆ pitaux de Paris, Universite´ Rene´ Descartes (Paris V),
Paris, France

Source: Brain © The Author (2010). Published by Oxford University Press on behalf of the Guarantors of Brain.(12/07/10)